Literature DB >> 7773028

[Hypercalcemia in cancer patients. Who, when and how to treat?].

R Bergeron1, N Martin, A Moreau.   

Abstract

The most frequent, potentially fatal, metabolic complication in cancer patients is hypercalcemia. After a discussion of cancer-associated hypercalcemia, we propose an individualized intervention model based on an analysis of the clinical situation, the prognosis, and available treatment options.

Entities:  

Mesh：

Year:  1995        PMID： 7773028      PMCID： PMC2148020     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN： 0008-350X            Impact factor:   3.275


  10 in total

Review 1.  Management of acute hypercalcemia.

Authors:  J P Bilezikian
Journal:  N Engl J Med       Date:  1992-04-30       Impact factor: 91.245

Review 2.  The pathogenesis of coronary artery disease and the acute coronary syndromes (1).

Authors:  V Fuster; L Badimon; J J Badimon; J H Chesebro
Journal:  N Engl J Med       Date:  1992-01-23       Impact factor: 91.245

3.  Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia.

Authors:  R Gucalp; P Ritch; P H Wiernik; P R Sarma; A Keller; S P Richman; K Tauer; J Neidhart; L E Mallette; R Siegel
Journal:  J Clin Oncol       Date:  1992-01       Impact factor: 44.544

4.  Cancer-associated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients.

Authors:  S H Ralston; S J Gallacher; U Patel; J Campbell; I T Boyle
Journal:  Ann Intern Med       Date:  1990-04-01       Impact factor: 25.391

5.  Maintenance etidronate in the prevention of malignancy-associated hypercalcemia.

Authors:  J H Schiller; P Rasmussen; A B Benson; R S Witte; R S Bockman; H A Harvey; E S Siris; D L Citrin; F A Greco; J L Stock
Journal:  Arch Intern Med       Date:  1987-05

6.  Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages.

Authors:  S R Nussbaum; J Younger; C J Vandepol; R F Gagel; M A Zubler; R Chapman; I C Henderson; L E Mallette
Journal:  Am J Med       Date:  1993-09       Impact factor: 4.965

Review 7.  Update on the medical treatment of hypercalcemia of malignancy.

Authors:  T G Hall; R A Schaiff
Journal:  Clin Pharm       Date:  1993-02

8.  Gallium nitrate for acute treatment of cancer-related hypercalcemia. A randomized, double-blind comparison to calcitonin.

Authors:  R P Warrell; R Israel; M Frisone; T Snyder; J J Gaynor; R S Bockman
Journal:  Ann Intern Med       Date:  1988-05       Impact factor: 25.391

Review 9.  Medical treatment of hypercalcemia.

Authors:  R A Schaiff; T G Hall; R S Bar
Journal:  Clin Pharm       Date:  1989-02

Review 10.  The hypercalcemia of malignancy: pathogenesis and management.

Authors:  G R Mundy; T J Martin
Journal:  Metabolism       Date:  1982-12       Impact factor: 8.694
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.